GHK-Cu SparkNotes
What Is It?
GHK-Cu (glycyl-histidyl-lysine copper) is a naturally occurring tripeptide-copper complex first isolated from human blood plasma in 1973. It declines ~60% with age (200 ng/mL at 20 → 80 ng/mL at 60), which correlates with reduced regenerative capacity. It modulates ~31% of the human genome (~4,000 genes) across collagen, antioxidant, anti-inflammatory, and DNA repair pathways.
Key Mechanisms (TL;DR)
- Collagen & ECM: Upregulates collagen I, III, elastin, decorin (up to +302%)
- Antioxidant defense: Activates Nrf2 (+56%), SOD, catalase, metallothionein (+142%)
- Anti-inflammatory: Suppresses TNF, IL-17A; boosts IL-18 binding protein (+295%)
- DNA repair: Upregulates 47 repair genes (PARP3, RAD50, MRE11A)
- Apoptosis: Reactivates caspases — may have anti-cancer relevance
- Primary pathways: TGF-β ↑, NF-κB ↓, Nrf2/ARE ↑, integrin signaling ↑
What the Human Trials Show
| Endpoint | Result | Study |
|---|---|---|
| Wrinkle volume reduction | 55.8% vs control | Badenhorst 2016 (n=40, RCT) |
| Collagen production | 70% of women improved (beat vitamin C & tretinoin) | Abdulghani 1998 (n=20) |
| Diabetic wound closure | 40% faster healing | Mulder 1994 (RCT) |
| Collagen density increase | 28% average (top quartile: 51%) | Yuvan Research 2023 (n=21) |
| Skin density & thickness | Significant improvement | Leyden 2002 (n=71) |
Caveat: All trials are small (20–71 subjects), short (8–12 weeks), mostly industry-funded, and none are registered on ClinicalTrials.gov. Results are consistent but not yet validated at scale.
Promising Preclinical Areas (No Human Trials Yet)
- Alzheimer's: Reduced amyloid plaques & improved memory in transgenic mice (intranasal, 12 weeks)
- COPD/Lung fibrosis: Reversed emphysema gene signature; reduced fibrosis in mouse models
- Cancer: Reversed 70% of metastatic colon cancer gene overexpression (Broad Institute screen); reactivated apoptosis in neuroblastoma & lymphoma cells in vitro
- Hair growth: Activated follicles in 6 days vs 9 for minoxidil in mice
Safety Profile
40+ years of use with no serious adverse events in published literature.
Minor/occasional side effects: mild redness, stinging (especially at high concentrations), temporary skin purging, rare contact dermatitis (copper-sensitive individuals).
Contraindications: Wilson's disease, copper metabolism disorders. Insufficient data for pregnancy/lactation.
Safety margin: therapeutic doses are >5,000× below toxic thresholds.
Dosing Guide
Topical
| Use Case | Concentration | Frequency | Duration |
|---|---|---|---|
| Eye area (periorbital) | 0.5–2% | 1–2× daily | 12 weeks |
| Face (general anti-aging) | 2–4% | 1–2× daily | 8–12 weeks |
| Post-procedure recovery | 0.05% | Per protocol | As needed |
| Scalp / hair | 0.02–0.5% | Daily | 16+ weeks |
Vehicle matters: Nano-lipid carriers and liposomal formulations outperform standard bases. A 1:9 ratio with low-MW hyaluronic acid showed 25× increased collagen IV synthesis in vitro.
Injectable (Subcutaneous)
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| Standard | 1–2 mg | Daily | 30 days |
| Moderate | 2 mg | 3×/week | 8–16 weeks |
| Conservative start | 1.0 mg → titrate to 1.5–2.0 mg | Daily | 30 days |
Reconstitution: 3 mL bacteriostatic water per 50 mg vial. Store refrigerated, use within 30 days.
Intranasal (Research Only)
15 mg/kg in 20 µL saline via atomizer — daily or 3×/week for 8–12 weeks. Used in Alzheimer's mouse studies; no human trial data.
Synergies Worth Noting
- GHK-Cu + red LED (625–635 nm): 12.5× cell viability increase, 230% more bFGF vs LED alone
- GHK-Cu + low-MW hyaluronic acid (1:9): 25.4× collagen IV synthesis
- GHK-Cu outperformed: Vitamin C, tretinoin, and Matrixyl 3000 in head-to-head comparisons
Bottom Line
GHK-Cu has strong mechanistic evidence, a clean safety record, and consistent (if small) clinical trial results for skin aging and wound healing. It beats several standard actives in head-to-head comparisons. The neuro, lung, and cancer applications are exciting but still preclinical. The biggest gap: no large-scale Phase III trials exist for any indication.